Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech, Inc. announced that Ms. Wang Yan, who has served as a joint company secretary since November 2021, is now fully qualified to act as the company secretary under Hong Kong Stock Exchange rules. Consequently, a further waiver for her role is no longer necessary. Despite this qualification, the company will maintain its joint company secretaries arrangement, with Ms. Chong Wan Kai continuing to assist Ms. Wang. This move aims to uphold a high standard of corporate governance, ensuring compliance and operational efficiency.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, known for its work in the pharmaceutical and biotech industries. The company focuses on the development and commercialization of monoclonal antibody biosimilars and innovative biologics.
YTD Price Performance: -0.63%
Average Trading Volume: 272,719
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$12.8B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.